fexofenadine has been researched along with Itching in 17 studies
fexofenadine: a second generation antihistamine; metabolite of the antihistaminic drug terfenadine; structure in first source; RN refers to HCl
fexofenadine : A piperidine-based anti-histamine compound.
| Excerpt | Relevance | Reference |
|---|---|---|
| "H1-antihistamines are the first-line treatment of chronic idiopathic urticaria (CIU), but CIU is occasionally refractory to the conventional treatment doses." | 9.17 | Comparison of the efficacy of fexofenadine 120 and 240 mg/day on chronic idiopathic urticaria and histamine-induced skin responses in Japanese populations. ( Kabashima, K; Miyachi, Y; Nakahigashi, K; Tanizaki, H, 2013) |
| "Fexofenadine (n = 201) significantly decreased the severity of pruritus compared with placebo (n = 199) (mean change in score -0." | 9.10 | Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebo-controlled, parallel-group study. ( Harada, S; Inagi, M; Kawashima, M; Nakagawa, H; Noguchi, T; Tango, T, 2003) |
| "In this 4-week, multicenter, placebo-controlled study, 439 patients with moderate to severe pruritus and urticaria received 1 of 4 oral doses of fexofenadine HCl (20, 60, 120, or 240 mg twice a day) or placebo." | 9.09 | A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. ( Finn, AF; Fretwell, R; Kaplan, AP; Long, J; Qu, R, 1999) |
| " In this study, we investigated the anti-pruritic effect of the antihistamine, fexofenadine, on the itch of contact dermatitis that was induced by topical application of diphenylcyclopropenone for the treatment for alopecia areata." | 7.73 | Fexofenadine, an H1-receptor antagonist, partially but rapidly inhibits the itch of contact dermatitis induced by diphenylcyclopropenone in patients with alopecia areata. ( Arakawa, S; Fujiwara, S; Hatano, Y; Katagiri, K, 2006) |
| "H1-antihistamines are the first-line treatment of chronic idiopathic urticaria (CIU), but CIU is occasionally refractory to the conventional treatment doses." | 5.17 | Comparison of the efficacy of fexofenadine 120 and 240 mg/day on chronic idiopathic urticaria and histamine-induced skin responses in Japanese populations. ( Kabashima, K; Miyachi, Y; Nakahigashi, K; Tanizaki, H, 2013) |
| "Fexofenadine (n = 201) significantly decreased the severity of pruritus compared with placebo (n = 199) (mean change in score -0." | 5.10 | Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebo-controlled, parallel-group study. ( Harada, S; Inagi, M; Kawashima, M; Nakagawa, H; Noguchi, T; Tango, T, 2003) |
| "In this 4-week, multicenter, placebo-controlled study, 439 patients with moderate to severe pruritus and urticaria received 1 of 4 oral doses of fexofenadine HCl (20, 60, 120, or 240 mg twice a day) or placebo." | 5.09 | A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. ( Finn, AF; Fretwell, R; Kaplan, AP; Long, J; Qu, R, 1999) |
| "Pretreatment with fexofenadine during venom immunotherapy reduces local allergic reactions and generalized symptoms of the urticaria and angioedema type." | 5.09 | Reduction of side-effects from ultrarush immunotherapy with honeybee venom by pretreatment with fexofenadine: a double-blind, placebo-controlled trial. ( Hari, Y; Müller, U; Reimers, A, 2000) |
| " However, fexofenadine probably leads to a small improvement in patient-assessed pruritus, with probably no significant difference in the amount of treatment used to prevent eczema flares." | 5.01 | Oral H1 antihistamines as 'add-on' therapy to topical treatment for eczema. ( Apfelbacher, CJ; Böhmer, MM; Carter, B; Jupiter, A; Matterne, U; Weisshaar, E, 2019) |
| "Urticaria is mainly caused by mast cell-derived histamine through the histamine H(1) receptor." | 3.78 | Effects of bepotastine and fexofenadine on histamine-induced flare, wheal and itch. ( Fukuoka, M; Ikoma, A; Kabashima, K; Miyachi, Y; Tanizaki, H, 2012) |
| " In this study, we investigated the anti-pruritic effect of the antihistamine, fexofenadine, on the itch of contact dermatitis that was induced by topical application of diphenylcyclopropenone for the treatment for alopecia areata." | 3.73 | Fexofenadine, an H1-receptor antagonist, partially but rapidly inhibits the itch of contact dermatitis induced by diphenylcyclopropenone in patients with alopecia areata. ( Arakawa, S; Fujiwara, S; Hatano, Y; Katagiri, K, 2006) |
| "Levocetirizine was more inhibitory than fexofenadine on wheal, flare and pruritus (p < 0." | 2.78 | The inhibition by levocetirizine and fexofenadine of the histamine-induced wheal and flare response in healthy Caucasian and Japanese volunteers. ( Church, MK; Maurer, M; Schoepke, N, 2013) |
| "Fexofenadine (180 mg/d) was taken during the run-in period and subsequently throughout the study and follow-up as required." | 2.73 | Narrowband ultraviolet B phototherapy is beneficial in antihistamine-resistant symptomatic dermographism: a pilot study. ( Borzova, E; Grattan, CE; Konstantinou, GN; Leslie, KS; Rutherford, A, 2008) |
| "Treatment with fexofenadine resulted in inhibition of allergen-induced symptoms and increased vascular permeability, but not the release of histamine and tryptase." | 2.70 | Effects of fexofenadine on the early response to nasal allergen challenge. ( Allocco, FT; Baroody, FM; deTineo, M; Naclerio, RM; Votypka, V, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 9 (52.94) | 29.6817 |
| 2010's | 7 (41.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Matterne, U | 1 |
| Böhmer, MM | 1 |
| Weisshaar, E | 1 |
| Jupiter, A | 1 |
| Carter, B | 1 |
| Apfelbacher, CJ | 1 |
| Tanizaki, H | 2 |
| Nakahigashi, K | 1 |
| Miyachi, Y | 2 |
| Kabashima, K | 2 |
| Hashimoto, T | 1 |
| Satoh, T | 1 |
| Borzova, E | 1 |
| Rutherford, A | 1 |
| Konstantinou, GN | 1 |
| Leslie, KS | 1 |
| Grattan, CE | 1 |
| Kamei, H | 1 |
| Isaji, A | 1 |
| Noda, Y | 1 |
| Ishikawa, K | 1 |
| Senzaki, K | 1 |
| Yamada, K | 1 |
| Sugiura, K | 1 |
| Tomita, Y | 1 |
| Nabeshima, T | 1 |
| Ikoma, A | 1 |
| Fukuoka, M | 1 |
| Schoepke, N | 1 |
| Church, MK | 1 |
| Maurer, M | 1 |
| Scherer, CR | 1 |
| Lerche, C | 1 |
| Decher, N | 1 |
| Dennis, AT | 1 |
| Maier, P | 1 |
| Ficker, E | 1 |
| Busch, AE | 1 |
| Wollnik, B | 1 |
| Steinmeyer, K | 1 |
| Allocco, FT | 1 |
| Votypka, V | 1 |
| deTineo, M | 1 |
| Naclerio, RM | 1 |
| Baroody, FM | 1 |
| Kawashima, M | 1 |
| Tango, T | 1 |
| Noguchi, T | 1 |
| Inagi, M | 1 |
| Nakagawa, H | 1 |
| Harada, S | 1 |
| Lennox, RD | 2 |
| Leahy, MJ | 1 |
| Shikiar, R | 1 |
| Harding, G | 1 |
| Leahy, M | 1 |
| Katagiri, K | 1 |
| Arakawa, S | 1 |
| Hatano, Y | 1 |
| Fujiwara, S | 1 |
| Benhamou, AH | 1 |
| Vanini, G | 1 |
| Lantin, JP | 1 |
| Eigenmann, PA | 1 |
| Finn, AF | 1 |
| Kaplan, AP | 1 |
| Fretwell, R | 1 |
| Qu, R | 1 |
| Long, J | 1 |
| Reimers, A | 1 |
| Hari, Y | 1 |
| Müller, U | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Efficacy and Consistency of Action of Levocetirizine 5 mg Once Daily With Fexofenadine 60 mg Twice Daily in the Histamine Induced Wheal, Flare and Itch Response[NCT01586091] | Phase 4 | 18 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Flaire diameter was measured with a transparent ruler as the mean of the largest diameter and the diameter at right angles to this. (NCT01586091)
Timeframe: 24 hours per treatment
| Intervention | mm (Mean) |
|---|---|
| Placebo | 69.4 |
| Levocetirizin | 20.4 |
| Fexofenadine | 39.9 |
"We measured drug concentrations and various aspects of skin provocation testing such as itch intensity and wheal size. Measurements made at each time point were as followed: Pruritus was assessed every 30 s for 10 min after SPT using a visual analogue scale (VAS) score with a 0 and 100 at the two ex- tremes of an unmarked 100 mm line with higher values indicating greater puritus. The mean VAS for each 10 min was calculated and used as a primary end Point." (NCT01586091)
Timeframe: up to 10 minutes after skin prick test performed 24 hours after drug administration
| Intervention | mm (Mean) |
|---|---|
| Levocetirizin | 11.5 |
| Fexofenadine | 25.4 |
| Placebo | 46.0 |
Wheal volume was measured by a non-contact three dimensional measurement system (PRIMOS contact, GFM Messtechnik GmbH, Teltow, Germany). (NCT01586091)
Timeframe: 24 hours per treatment
| Intervention | cm3 (Mean) |
|---|---|
| Placebo | 174.6 |
| Levocetirizin | 35.2 |
| Fexofenadine | 106.3 |
1 review available for fexofenadine and Itching
| Article | Year |
|---|---|
Oral H1 antihistamines as 'add-on' therapy to topical treatment for eczema.
Topics: Administration, Oral; Administration, Topical; Adult; Cetirizine; Chemotherapy, Adjuvant; Child; Ecz | 2019 |
9 trials available for fexofenadine and Itching
| Article | Year |
|---|---|
Comparison of the efficacy of fexofenadine 120 and 240 mg/day on chronic idiopathic urticaria and histamine-induced skin responses in Japanese populations.
Topics: Adult; Chronic Disease; Cross-Over Studies; Double-Blind Method; Female; Histamine; Histamine H1 Ant | 2013 |
Narrowband ultraviolet B phototherapy is beneficial in antihistamine-resistant symptomatic dermographism: a pilot study.
Topics: Adult; Drug Resistance; Female; Histamine H1 Antagonists; Humans; Male; Pilot Projects; Prospective | 2008 |
Effects of single therapeutic doses of promethazine, fexofenadine and olopatadine on psychomotor function and histamine-induced wheal- and flare-responses: a randomized double-blind, placebo-controlled study in healthy volunteers.
Topics: Adolescent; Dibenzoxepins; Double-Blind Method; Female; Histamine H1 Antagonists; Humans; Male; Olop | 2012 |
The inhibition by levocetirizine and fexofenadine of the histamine-induced wheal and flare response in healthy Caucasian and Japanese volunteers.
Topics: Adult; Asian People; Cetirizine; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2013 |
Effects of fexofenadine on the early response to nasal allergen challenge.
Topics: Adolescent; Adult; Allergens; Biomarkers; Capillary Permeability; Cross-Over Studies; Double-Blind M | 2002 |
Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebo-controlled, parallel-group study.
Topics: Adolescent; Adult; Aged; Anti-Allergic Agents; Dermatitis, Atopic; Dermatologic Agents; Double-Blind | 2003 |
Validation of the Dermatology Life Quality Index as an outcome measure for urticaria-related quality of life.
Topics: Chronic Disease; Dermatology; Dose-Response Relationship, Drug; Double-Blind Method; Histamine H1 An | 2004 |
A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria.
Topics: Adolescent; Adult; Aged; Child; Chronic Disease; Double-Blind Method; Female; Histamine H1 Antagonis | 1999 |
Reduction of side-effects from ultrarush immunotherapy with honeybee venom by pretreatment with fexofenadine: a double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Angioedema; Anti-Allergic Agents; Bee Venoms; Double-Blind Method; Drug Therapy, | 2000 |
7 other studies available for fexofenadine and Itching
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Generalized pruritus in primary sclerosing cholangitis: implications of histamine release by lysophosphatidic acid.
Topics: Adolescent; Cholangitis, Sclerosing; Histamine H1 Antagonists, Non-Sedating; Histamine Release; Huma | 2015 |
Effects of bepotastine and fexofenadine on histamine-induced flare, wheal and itch.
Topics: Adult; Female; Histamine; Histamine H1 Antagonists, Non-Sedating; Humans; Male; Piperidines; Pruritu | 2012 |
The antihistamine fexofenadine does not affect I(Kr) currents in a case report of drug-induced cardiac arrhythmia.
Topics: Aged; Amino Acid Sequence; Amino Acid Substitution; Animals; Arrhythmias, Cardiac; Base Sequence; Bl | 2002 |
Minimal important difference (MID) of the Dermatology Life Quality Index (DLQI): results from patients with chronic idiopathic urticaria.
Topics: Adolescent; Adult; Aged; Child; Chronic Disease; Clinical Trials, Phase III as Topic; Data Interpret | 2005 |
Fexofenadine, an H1-receptor antagonist, partially but rapidly inhibits the itch of contact dermatitis induced by diphenylcyclopropenone in patients with alopecia areata.
Topics: Adolescent; Adult; Aged; Alopecia Areata; Cohort Studies; Cyclopropanes; Dermatitis, Contact; Dose-R | 2006 |
Antihistamine and sodium cromoglycate medication for food cold water exercise-induced anaphylaxis.
Topics: Adolescent; Anaphylaxis; Anti-Asthmatic Agents; Cold Temperature; Cromolyn Sodium; Drug Therapy, Com | 2007 |